Axicabtagene Ciloleucel

證據等級: L5

預測適應症: 0 個

Axicabtagene Ciloleucel: Repurposing Evaluation — Insufficient Evidence Pack

One-Sentence Summary

Axicabtagene ciloleucel (DB13915) is a CD19-directed CAR-T cell immunotherapy; however, the current Evidence Pack contains no original indication records, no TxGNN-predicted indications, and no mechanism-of-action data. Without a predicted new indication, a standard repurposing evaluation cannot be completed at this time. The recommended action is to remediate all Blocking/High-severity data gaps before re-running the pipeline.

Quick Overview

Item	Content
Original Indication	Not recorded in Evidence Pack
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	N/A (no predictions generated)
Finland Market Status	Not marketed (0 authorisations)
Number of Authorizations	0
Recommended Decision	Hold

Why No Prediction Is Available

The predicted_indications array in the Evidence Pack is empty. This typically occurs for one of two reasons:

Model scope: The TxGNN knowledge graph may not include the DrugBank node for DB13915 (axicabtagene ciloleucel) because CAR-T cell therapies are living-cell products whose graph representation differs from small-molecule drugs.
Pipeline gap: The prediction step may not have been executed, or the disease-mapping step (KG → MeSH/ICD) produced no matched candidates above threshold.

Currently, detailed mechanism-of-action data is also unavailable. Based on known information, axicabtagene ciloleucel belongs to the CD19-targeting CAR-T cell therapy class; its efficacy in relapsed/refractory large B-cell lymphoma has been established in registrational trials, and mechanistically its approach could in principle extend to other CD19-expressing haematological malignancies — but this cannot be formally evaluated without Evidence Pack data.

Clinical Trial Evidence

Currently no related clinical trials registered in this Evidence Pack.

Literature Evidence

Currently no related literature available in this Evidence Pack.

Finland Market Information

No marketing authorisations on file for axicabtagene ciloleucel in this Evidence Pack.

Cytotoxicity

Axicabtagene ciloleucel is an antineoplastic cellular product (CAR-T immunotherapy targeting CD19). The following is noted from the DrugBank record retrieved in this run; detailed package-insert toxicity data was not parsed into the Evidence Pack.

Item	Content
Cytotoxicity Classification	Cellular immunotherapy (CAR-T; not conventional cytotoxic)
Myelosuppression Risk	High — cytokine release syndrome and haematological toxicity are class effects of CAR-T therapies
Emetogenicity Classification	Low (primary toxicity is CRS/neurotoxicity, not emetogenicity)
Monitoring Items	CBC with differential, liver function, renal function, neurological status, ferritin, CRP (CRS monitoring)
Handling Protection	Must follow guidelines for handling of genetically modified cellular products; standard cytotoxic handling precautions apply

Note: The above is based on CAR-T class knowledge. Please refer to the full package insert (Yescarta® SmPC) for product-specific warnings and precautions.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack contains no predicted indications, no original indication records, and no mechanism-of-action data; a drug repurposing evaluation cannot be meaningfully completed or scored without these inputs.

To proceed, the following is needed:

[DG001 — Blocking] Retrieve TFDA (or EMA/FDA) package insert PDF and parse warnings, contraindications, and approved indications
[DG002 — High] Query DrugBank API for MOA, pharmacology, and drug categories for DB13915
Re-run TxGNN pipeline after confirming that the DB13915 node is present in the knowledge graph and that the prediction + disease-mapping steps complete successfully
Verify KG node type: Confirm whether axicabtagene ciloleucel is modelled as a small-molecule node or a biologic/cell-therapy node in the TxGNN graph, as this affects prediction coverage
Once predictions are available, re-generate this Evidence Pack (v5+) and re-run the evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.